https://allsci.com/news/biotech/kb113-bcc-treatment-krystal-biotechs-shows-lesion/ AllScien 2026-10-15T16:19:55.448919Z Krystal’s KB113 shrinks injected and untreated skin tumors in three-patient Gorlin study https://allsci.com/news/biotech/vqw-765-social-anxiety-vandas-misses-phase-iii/ AllScien 2026-10-15T16:06:58.622028Z Vanda puts anxiety drug VQW-765 on hold after Phase III failure https://allsci.com/news/biotech/fshd-treatment-altay-therapeutics-raises-usd-37m/ AllScien 2026-10-15T15:55:54.662799Z Altay raises USD 37m Series A to push oral DUX4 inhibitor into clinic for FSHD https://allsci.com/news/clinical-trials/first-in-human-trials/cellio-therapeutics-ipsc-derived-retinal-pigment-epithelium-c-001-enters-phase-i-for-rpe-mediated-maculopathy/ AllScien 2026-10-15T15:43:19.434530Z Cellio Therapeutics' iPSC-derived retinal pigment epithelium C.001 enters Phase I for RPE-mediated maculopathy https://allsci.com/news/biotech/ai-drug-discovery-deep-origin-and-bioage-labs/ AllScien 2026-10-15T14:12:06.619657Z BioAge and Deep Origin report first validated hits from AI drug discovery collaboration https://allsci.com/news/biotech/lag-3-research-immutep-and-monash-university/ AllScien 2026-10-15T14:05:10.840187Z Australia's Immutep and Monash University secure ARC grant for LAG-3 structural research https://allsci.com/news/licensing-and-partnerships/diazepam-buccal-film-eton-pharmaceuticals/ AllScien 2026-10-15T13:54:15.865545Z Eton Pharma licenses Libervant diazepam buccal film for US epilepsy seizure clusters https://allsci.com/news/biotech/ocu400-gene-therapy-ocugen-licenses-to-roots/ AllScien 2026-10-15T13:48:16.643257Z Ocugen licenses OCU400 gene therapy to Roots Pharmaceutical for MENA region https://allsci.com/news/biotech/claudin-1-adc-alentis-and-pinotbio-team-up-to/ AllScien 2026-10-15T13:42:02.082291Z Alentis and PinotBio team up to advance next-generation claudin-1 ADCs in oncology https://allsci.com/news/clinical-trials/oral-ecnoglutide-verdiva-bio-terminates-phase-ii/ AllScien 2026-10-15T13:25:27.502723Z Verdiva halts oral ecnoglutide weight-maintenance trial, citing business decision https://allsci.com/news/biotech/envudeucitinib-psoriasis-phase-3-data-show/ AllScien 2026-10-15T13:16:20.963723Z Alumis reports sustained scalp and itch improvements with envudeucitinib ahead of filing https://allsci.com/news/licensing-and-partnerships/3d-printed-oral-medicines-johnson-johnson-strikes/ AllScien 2026-10-15T13:05:23.348867Z J&J strikes collaboration and equity deal with China's Triastek for 3D-printed oral peptide tech https://allsci.com/news/biotech/zealand-pharma-taps-generate-biomedicines-ai/ AllScien 2026-10-14T18:20:44.801642Z Zealand taps Generate’s AI platform for multispecific obesity therapies in USD 30 million deal https://allsci.com/news/biotech/vir-biotechnology-gilead-strikes-usd-90m-upfront/ AllScien 2026-10-14T18:11:43.048024Z Vir Biotechnology strikes USD 90m upfront deal with Gilead to build masked TCEs https://allsci.com/news/clinical-trials/biomea-fusion-bmf-650-fusions-shows-1532-weight/ AllScien 2026-10-14T17:33:16.926504Z Biomea reports early weight-loss signal for oral GLP-1 drug, seeks development partner https://allsci.com/news/biotech/kras-g12d-inhibitor-verastems-vs-7375-achieves-41/ AllScien 2026-10-14T17:12:31.200632Z Verastem’s KRAS G12D inhibitor shrinks pancreatic tumors in 41% of patients https://allsci.com/news/biotech/vs-7375-kras-g12d-verastem-raises-usd-250m-to/ AllScien 2026-10-14T16:43:21.497371Z Verastem raises USD 250m to advance VS-7375 KRAS G12D program https://allsci.com/news/clinical-trials/ulcerative-colitis-trial-first-patient-dosed-in/ AllScien 2026-10-14T16:28:28.079566Z GSK and Oxford Uni begin IL-18 antibody study to map treatment effects in ulcerative colitis https://allsci.com/news/biotech/eq504-trial-equillium-clears-australian/ AllScien 2026-10-14T16:16:15.189654Z Equillium clears Australian hurdle for first human trial of ulcerative colitis AhR modulator https://allsci.com/news/biotech/itr-251-clinical-trial-iteria-biopharma-registers/ AllScien 2026-10-14T15:10:30.146506Z Iteria plans first human trial of MAO-A inhibitor targeting advanced cancer https://allsci.com/news/biotech/alaunos-therapeutics-acquisition-acquires-velaris/ AllScien 2026-10-14T11:36:27.861932Z Alaunos pivots to PAH with Velaris acquisition and USD 350m financing https://allsci.com/news/clinical-trials/risankizumab-crohns-disease-abbvies-met-phase-iii/ AllScien 2026-10-14T11:12:06.124326Z AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpoints https://allsci.com/news/biotech/souffle-therapeutics-secures-oversubscribed-usd/ AllScien 2026-10-14T10:33:38.010651Z Soufflé rises with USD 135m Series B to advance FSHD and heart failure therapies https://allsci.com/news/biotech/hidradenitis-suppurativa-bispecific-antibody/ AllScien 2026-10-14T10:23:49.876177Z Shandong First Medical researchers identify IL-17A/IL-36 axis as therapeutic target in HS https://allsci.com/news/biotech/sec61-inhibitors-enodia-therapeutics-strikes/ AllScien 2026-10-13T17:41:35.147618Z Pfizer partners with Enodia on Sec61 protein degradation therapies in deal exceeding USD 500m https://allsci.com/news/biotech/alk7-obesity-therapy-roche-licenses-ronas-rnai-in/ AllScien 2026-10-13T17:37:20.346357Z Roche licenses Rona's ALK7 RNAi obesity therapy in deal worth up to USD 1.16b https://allsci.com/news/biotech/roginolisib-pi3k-nature-communications-papers/ AllScien 2026-10-13T17:33:08.983427Z Roginolisib studies detail PI3Kδ inhibition mechanism and Phase I survival data in uveal melanoma https://allsci.com/news/licensing-and-partnerships/neurotrophic-keratitis-visara-licenses-nerve/ AllScien 2026-10-13T17:30:06.821288Z NovaBridge's Visara expands ophthalmology pipeline with USD 111m Hiteck licensing deal https://allsci.com/news/biotech/sirna-delivery-undecimal-bio-raises-usd-18m-seed/ AllScien 2026-10-13T17:25:53.127275Z Undecimal Bio raises USD 18m seed round to extend siRNA delivery beyond the liver https://allsci.com/news/clinical-trials/biontech-bnt113-biontechs-misses-phase-iii/ AllScien 2026-10-13T17:18:51.730642Z BioNTech's BNT113 misses Phase III PFS endpoint in head and neck cancer, OS analysis continues https://allsci.com/news/biotech/melflufen-glioblastoma-oncopeptides-shows-signs/ AllScien 2026-10-13T17:07:06.660405Z Oncopeptides' melflufen shows signs of blood-brain barrier penetration in early INSULA glioblastoma data https://allsci.com/news/clinical-trials/remigromig-dme-meets-non-inferiority-primary/ AllScien 2026-10-13T17:01:21.810553Z Merck's remigromig meets Phase III DME endpoint, but retinopathy safety signal emerges